Patents by Inventor Yoshiaki Kassai
Yoshiaki Kassai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230374128Abstract: The present invention provides a therapeutic agent for an immune/inflammatory disease comprising an anti-human TIGIT antibody, which activates a suppressive immune checkpoint molecule (TIGIT), as an active ingredient. Also, provided is an antibody having the following characteristics a) and b): a) the third CDR of heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 4 b) the third CDR of light chain variable region comprises the amino acid sequence of SEQ ID NO: 6.Type: ApplicationFiled: October 8, 2021Publication date: November 23, 2023Applicants: Keio University, Takeda Pharmaceutical Company LimitedInventors: Tsutomu TAKEUCHI, Akihiko YOSHIMURA, Katsuya SUZUKI, Masaru TAKESHITA, Marenori KOJIMA, Yoshiaki KASSAI, Taku KORO, Keiko SEKIYA, Tomoki YOSHIHARA, Ryutaro ADACHI
-
Publication number: 20230257708Abstract: Provided is a T cell receptor containing, as ? chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 1 to 3, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 4 to 6, as ? chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 7 to 9, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 10 to 12, and capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24.Type: ApplicationFiled: February 6, 2023Publication date: August 17, 2023Inventors: Tetsuya Nakatsura, Toshiaki Yoshikawa, Yasushi Uemura, Kyoko Fukuda, Shin Kaneko, Atsutaka Minagawa, Yoshiaki Kassai, Atsushi Matsuda
-
Patent number: 11603519Abstract: Provided is a T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24. A T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 28 or a complex of the peptide and HLA-A02. Disclosed T cell receptors are useful in treating or avoiding cancers which are associated with expression of glypican-3.Type: GrantFiled: February 5, 2018Date of Patent: March 14, 2023Assignees: National Cancer Center Japan, Kyoto University, Takeda Pharmaceutical Company LimitedInventors: Tetsuya Nakatsura, Toshiaki Yoshikawa, Yasushi Uemura, Kyoko Fukuda, Shin Kaneko, Atsutaka Minagawa, Yoshiaki Kassai, Atsushi Matsuda
-
Publication number: 20230000915Abstract: The present invention provides a system for providing a T cell product, including a T cell master cell bank and/or a T cell working cell bank.Type: ApplicationFiled: November 24, 2020Publication date: January 5, 2023Applicants: Kyoto University, Takeda Pharmaceutical Company LimitedInventors: Shin KANEKO, Suguru ARIMA, Maiko TAKIGUCHI, Yoshiaki KASSAI, Akira HAYASHI
-
Publication number: 20220099670Abstract: Disclosed is a method for detecting regulatory dendritic cells, the method comprising step a: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step b: identifying regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Also disclosed is a method for producing a cell population enriched for regulatory dendritic cells, the method comprising step 1: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step 2: obtaining a cell population enriched for regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Further disclosed is a cell population enriched for regulatory dendritic cells obtained by the method.Type: ApplicationFiled: January 31, 2021Publication date: March 31, 2022Applicants: Kyoto University, TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Shin KANEKO, Shoichi IRIGUCHI, Keiko SEKIYA, Yoshiaki KASSAI
-
Publication number: 20220089672Abstract: The present invention provides a variant of a T-cell receptor containing a combination of two polypeptides containing a constant region of a T cell receptor chain selected from the group consisting of ? chain, ? chain, ? chain and ? chain, wherein the polypeptide does not contain a complementarity determining region (CDR) of the T cell receptor chain, a complementarity determining region (CDR) of the ? chain, and a complementarity determining region (CDR) of the ? chain.Type: ApplicationFiled: December 26, 2019Publication date: March 24, 2022Applicants: Kyoto University, Takeda Pharmaceutical Company LimitedInventors: Shin KANEKO, Yoshiaki KASSAI, Akira HAYASHI
-
Publication number: 20210381006Abstract: The present invention provides a method for activating/proliferating T cells, including a step of contacting a cell population containing T cells with a nucleic acid delivery carrier having at least one kind of T cell activating ligand added to its surface, and a method for delivering a nucleic acid into T cells, the methods including a step of contacting a cell population containing T cells simultaneously with (a) a nucleic acid delivery carrier having at least one kind of T cell activating ligand added to its surface and containing a nucleic acid inside, or (b) at least one kind of T cell activating ligand, and a nucleic acid delivery carrier containing a nucleic acid inside and free of a T cell activating ligand added to its surface, a method for producing a medicament containing T cells and the like.Type: ApplicationFiled: October 17, 2019Publication date: December 9, 2021Applicant: Takeda Pharmaceutical Company LimitedInventors: Shinobu KUWAE, Satoru MATSUMOTO, Akira HAYASHI, Yoshiaki KASSAI, Kazuhide NAKAYAMA
-
Publication number: 20210301260Abstract: To enable stable supply of differentiated T cells, the present invention provides a method for producing, or a method for expansion culture, or a kit for expansion culture of a CD3-positive cell in which T cell marker CD3 is expressed on the cell membrane.Type: ApplicationFiled: August 8, 2019Publication date: September 30, 2021Inventors: Shin Kaneko, Yohei Kawai, Suguru Arima, Maiko Takiguchi, Kazuhide Nakayama, Yoshiaki Kassai, Akira Hayashi
-
Publication number: 20210130777Abstract: The present invention provides a method for producing a ??T cell from an induced pluripotent stem cell, wherein the induced pluripotent stem cell is derived from a cell other than an ??T cell.Type: ApplicationFiled: July 12, 2019Publication date: May 6, 2021Inventors: Shin Kaneko, Shoichi Iriguchi, Tatsuki Ueda, Yoshiaki Kassai, Akira Hayashi, Kazuhide Nakayama
-
Publication number: 20210102167Abstract: Provided is a method for producing a CD4/CD8 double positive cell, including the following steps: step 1: separating, from a cell population containing a hematopoietic progenitor cell, a cell expressing one or more kinds of molecules selected from the first group consisting of CD24, CD62L, CD90, CD143, CD263, Notch3, CD32, CD39, CD49a, CD164, CD317, CD200, CD218a, CD7, CD144, CD56, CD226, CD262 and CD325, and/or a cell not expressing one or more kinds of molecules selected from the second group consisting of CD49f, CD51, CD102, CD42b, CD61, CD62P, CD69, CD102 and CD156c, and step 2: differentiating the cell separated in step 1 into a CD4/CD8 double positive cell.Type: ApplicationFiled: April 25, 2018Publication date: April 8, 2021Inventors: Shin Kaneko, Shoichi Iriguchi, Yuta Mishima, Yoshiaki Kassai, Akira Hayashi, Suguru Arima
-
Publication number: 20200010804Abstract: Provided is a T cell receptor containing, as ? chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 1 to 3, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 4 to 6, as ? chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 7 to 9, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 10 to 12, and capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24.Type: ApplicationFiled: February 5, 2018Publication date: January 9, 2020Inventors: Tetsuya Nakatsura, Toshiaki Yoshikawa, Yasushi Uemura, Kyoko Fukuda, Shin Kaneko, Atsutaka Minagawa, Yoshiaki Kassai, Atsushi Matsuda